Results 151 to 160 of about 26,394 (258)

Improving Gallbladder Cancer Outcomes with Antibody-Based Therapies and Immunological Profiling: A Literature Review. [PDF]

Antibodies (Basel)
Caglevic C, Contreras-Torrez MA, Reyes-Cosmelli F, Uribe-Maturana R, Mahave M, Caire N, Villanueva-Olivares L, Cid F, Lladser A, Sapunar J.   +9 more
europepmc   +1 more source

Current State of Moderate Congenital Haemophilia A and the Need for Preventive Treatment

Haemophilia, EarlyView.
ABSTRACT Introduction The severity of haemophilia A is classified by the degree of factor VIII (FVIII) deficiency, rather than by clinical manifestations. However, FVIII activity alone does not necessarily accurately reflect clinical severity such as bleeding tendency, and patients with mild‐to‐moderate haemophilia A can experience significant disease ...
Masahiro Takeyama, Atsuki Yamashita, Tomoko Yamaguchi, Takahiro Ito, Yui Sugawara, Akiko Ioka, Tazuko Tokugawa   +6 more
wiley   +1 more source

Safely targeting combination TNF and IL-23 using a gut-restricted and orally delivered therapeutic approach: proof-of-concept for the development of SOR102 in ulcerative colitis. [PDF]

Transl Gastroenterol Hepatol
Faggiani I, Panaccione R, Ma C.
europepmc   +1 more source

The XX Factor in Hemophilia: Diagnostic, Therapeutic, and Research Gaps for Women and Girls

Haemophilia, EarlyView.
ABSTRACT Introduction Hemophilia has traditionally been viewed as an X‐linked disorder affecting men and boys, with women and girls labeled as “carriers”, presumed to be clinically unaffected. This paradigm has contributed to under‐recognition, delayed diagnosis, and undertreatment of females with hemophilia‐associated genotypes despite an increasingly
Kelsey Uminski, Ellen Cusano
wiley   +1 more source

Bispecific antibodies targeting herpes simplex virus glycoproteins B and D. [PDF]

Front Immunol
Atanasiu D, Saw WT, Cairns TM, Friedman HM, Cohen GH.   +4 more
europepmc   +1 more source

BLIMP‐1 and CD39 expression define human effector memory regulatory T cells in blood and recall responses to viruses

Immunology &Cell Biology, EarlyView.
This study found that BLIMP‐1 is highly expressed in activated effector/memory human regulatory T cells, especially CD39+ Tregs, where it is associated with increased IL‐10 production and a conserved phenotype across blood and lung tissues during immune responses such as SARS‐CoV‐2 infection.
Chansavath Phetsouphanh, Laura Cook, Katherine J. L. Jackson, Deirdre Cuff, Vera Klemm, Bikash Manandhar, Denise C. Hsu, Yin Xu, John J. Zaunders, Anthony D. Kelleher, Nabila Seddiki   +10 more
wiley   +1 more source

Efficacy and safety of BCMA- or GPRC5D-directed CD3 bispecific antibodies in relapsed/refractory multiple myeloma: a systematic review and meta-analysis of prospective clinical trials and real-world studies. [PDF]

Front Immunol
Li J, Abulaiti A, Li D, Zhao Y, Wahafu P, Maimaitiming M, Qiu S, Zhang Y, An Y, Wang W, Shi L, Yakufu M, Shu L, Li G, Liu Z.   +14 more
europepmc   +1 more source

A PD1‐CD137L Fusion Protein More Potently Enhances Anti‐Tumour Immune Responses Than Targeting PD‐L1 and CD137 Separately

Immunology, EarlyView.
A PD1‐CD137L fusion protein converts the immunoinhibitory PD‐L1 to an immunostimulatory signal and is more effective than targeting PD‐L1 and CD137 separately. ABSTRACT Tumour immune evasion frequently involves PD‐L1‐mediated inhibition of T cell activity, limiting the efficacy of PD1/PD‐L1 blockade, particularly in PD‐L1‐low or immunologically ‘cold ...
Runze Xia, Emily Pauline Nickles, Yu Mei, Thamizhanban Manoharan, Yi Tian Png, Beijia Liu, Rui Sun, Kang Yi Lee, Gloryn Chia, Chwee Ming Lim, Herbert Schwarz   +10 more
wiley   +1 more source

Brain interstitial fluid pharmacokinetics and therapeutic effect of a BBB penetrating amyloid beta antibody measured by microdialysis. [PDF]

Neurotherapeutics
Wik E, Dahlén AD, Julku U, Xiong M, Michno W, Syvänen S, Sehlin D.   +6 more
europepmc   +1 more source

Pathophysiology and emerging treatments for dermographic, cholinergic and cold urticaria

Journal of the European Academy of Dermatology and Venereology, EarlyView.
This review illustrates key proposed mast cell‐mediated activation pathways in dermographic, cholinergic and cold urticaria, highlighting IgE‐dependent and ‐independent mechanisms. These pathways are increasingly targeted by emerging drugs, aiming to interrupt mast cell activation and mediator release, offering more precise, mechanism‐based treatment ...
Mojca Bizjak‐Suran, Matjaž Fležar, Manuel Pedro Pereira   +2 more
wiley   +1 more source